Charles Schwab
GLSI icon

Charles Schwab’s Greenwich LifeSciences GLSI Stock Holding History

Charles Schwab’s Portfolio GLSI Stock Details GLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$401K Buy
17,098
+495
+3% +$12K ﹤0.01% 3279
2026
Q1 		$399K Sell
16,603
-2,438
-13% -$63.6K ﹤0.01% 3173
2025
Q4 		$400K Buy
19,041
+39
+0.2% +$410 ﹤0.01% 3216
2025
Q3 		$189K Sell
19,002
-47
-0.2% -$530 ﹤0.01% 3353
2025
Q2 		$173K Buy
19,049
+42
+0.2% +$399 ﹤0.01% 3389
2025
Q1 		$181K Buy
19,007
+2,552
+16% +$30.9K ﹤0.01% 3271
2024
Q4 		$185K Hold
16,455
– – ﹤0.01% 3338
2024
Q3 		$236K Sell
16,455
-1,999
-11% -$29.6K ﹤0.01% 3314
2024
Q2 		$319K Buy
+18,454
New +$270K ﹤0.01% 3354
2022
Q2 		– Sell
-10,191
Closed -$200K – 3580
2022
Q1 		$200K Buy
10,191
+372
+4% +$7.52K ﹤0.01% 3307
2021
Q4 		$239K Hold
9,819
– – ﹤0.01% 3333
2021
Q3 		$384K Hold
9,819
– – ﹤0.01% 3214
2021
Q2 		$442K Buy
+9,819
New +$371K ﹤0.01% 3194

Other funds holding GLSI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Charles Schwab's GLSI Position: Q2 2026 in Review

Charles Schwab increased its Greenwich LifeSciences (GLSI) stake by 3% in Q2 2026, buying an estimated $12K and bringing the position to 17,098 shares worth $401K. The position accounts for ﹤0.01% of the portfolio, ranked #3279.

Charles Schwab first reported a position in GLSI in Q2 2021 and has held it in 13 quarters since. The position peaked at $442K in Q2 2021. 58 funds tracked by Wall St. Rank hold GLSI as of Q2 2026.

  • Charles Schwab held 17,098 shares of Greenwich LifeSciences worth $401K as of Q2 2026.
  • Charles Schwab bought 495 Greenwich LifeSciences shares in Q2 2026, an estimated $12K.
  • Greenwich LifeSciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3279 holding.
  • Charles Schwab first reported a position in Greenwich LifeSciences in Q2 2021 and has held it in 13 quarters since.
  • Charles Schwab's Greenwich LifeSciences position peaked at $442K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.